SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
latest_posts
- 1
Experience Arranging: Planning for Epic Excursions - 2Zelensky warns of imminent massive Russian attack on Ukraine
- 3She's been a Bond girl and a mutant. Now she's grappling with Hollywood's obsession with 'eternal youth.'
- 4Figure out how to Guarantee Your Dental Embeds Endure forever
- 5Supreme Court case about ‘crisis pregnancy centers’ highlights debate over truthful advertising standards
- Involved Vehicles for Seniors: Track down the Best Picks for Solace and Dependability
- Independence from the rat race: How to Save and Contribute Shrewdly
- Wegovy maker Novo sharpens consumer focus with board role for Mars CEO
- April's full moon decides the date of Easter — here's how it works
- 4 Home Rec center Hardware Decisions for Little Spaces
- New movies to watch this weekend: See 'We Bury the Dead' in theaters, rent 'Wicked: For Good,' stream 'The Unbreakable Boy' on Starz
- Home Machine Basics: An Exhaustive Purchasing Guide
- These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- Scientists detect X-ray glow from interstellar comet 3I/ATLAS extending 250,000 miles into space
